JP2019506403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506403A5 JP2019506403A5 JP2018538596A JP2018538596A JP2019506403A5 JP 2019506403 A5 JP2019506403 A5 JP 2019506403A5 JP 2018538596 A JP2018538596 A JP 2018538596A JP 2018538596 A JP2018538596 A JP 2018538596A JP 2019506403 A5 JP2019506403 A5 JP 2019506403A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence represented
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662286616P | 2016-01-25 | 2016-01-25 | |
| US62/286,616 | 2016-01-25 | ||
| PCT/IB2017/050244 WO2017130076A1 (en) | 2016-01-25 | 2017-01-17 | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506403A JP2019506403A (ja) | 2019-03-07 |
| JP2019506403A5 true JP2019506403A5 (https=) | 2019-10-24 |
| JP6783312B2 JP6783312B2 (ja) | 2020-11-11 |
Family
ID=57956335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538596A Expired - Fee Related JP6783312B2 (ja) | 2016-01-25 | 2017-01-17 | がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190031765A1 (https=) |
| EP (1) | EP3408294A1 (https=) |
| JP (1) | JP6783312B2 (https=) |
| KR (2) | KR20180103150A (https=) |
| CN (1) | CN108473587A (https=) |
| AU (2) | AU2017211540B2 (https=) |
| BR (1) | BR112018014016A2 (https=) |
| CA (1) | CA2955184A1 (https=) |
| HK (1) | HK1259253A1 (https=) |
| MX (1) | MX2018008995A (https=) |
| RU (1) | RU2748949C2 (https=) |
| WO (1) | WO2017130076A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| KR20240017409A (ko) | 2017-04-13 | 2024-02-07 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CA3064804A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc |
| AU2018301393B2 (en) | 2017-07-11 | 2025-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019178852A1 (zh) * | 2018-03-23 | 2019-09-26 | 苏州丁孚靶点生物技术有限公司 | Ox40抗原多肽及其用途 |
| US12054554B2 (en) | 2018-04-10 | 2024-08-06 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof |
| CN110357961B (zh) * | 2018-04-10 | 2022-08-23 | 无锡智康弘义生物科技有限公司 | 抗人4-1bb单克隆抗体及其制备方法和用途 |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| CN112739339B (zh) | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| CA3141452A1 (en) * | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| KR20220070254A (ko) | 2019-09-25 | 2022-05-30 | 화이자 인코포레이티드 | Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제 |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| IL294557A (en) | 2020-01-07 | 2022-09-01 | Univ Texas | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| CN115362270A (zh) | 2020-01-29 | 2022-11-18 | 得克萨斯州大学系统董事会 | Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途 |
| JP7777533B2 (ja) | 2020-01-29 | 2025-11-28 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| EP4155319A4 (en) * | 2020-06-30 | 2024-06-12 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1BB BINDING PROTEIN AND ITS USE |
| CN114515335A (zh) * | 2020-11-19 | 2022-05-20 | 百奥泰生物制药股份有限公司 | 抗ox40抗体在治疗肿瘤或癌症中的应用 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| US11964978B2 (en) | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
| US20240182593A1 (en) * | 2021-05-27 | 2024-06-06 | Yuhan Corporation | Ox40 agonist and use thereof |
| CN116253799B (zh) * | 2021-09-09 | 2024-04-26 | 广东东阳光药业股份有限公司 | 抗4-1bb的激动型抗体及其应用 |
| WO2023056361A1 (en) | 2021-09-29 | 2023-04-06 | Board Of Regents, The University Of Texas System | Anti-hsp70 antibodies and therapeutic uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AP1261A (en) | 1998-02-24 | 2004-03-19 | Sisters Of Providence In Oregon | Composition containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response. |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| WO2006055697A2 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
| JP2008542354A (ja) | 2005-06-03 | 2008-11-27 | ファイザー・プロダクツ・インク | 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用 |
| PT2594590E (pt) * | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| BR112013033157A2 (pt) | 2011-06-30 | 2017-01-31 | Michelin & Cie | métodos e aparelhos para a instalação de um anel de banda de rodagem e uma carcaça de pneu |
| WO2013119202A1 (en) | 2012-02-06 | 2013-08-15 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using ox40 agonists |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| CN106413751A (zh) * | 2014-05-21 | 2017-02-15 | 辉瑞大药厂 | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 |
| MY193229A (en) * | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
-
2017
- 2017-01-17 CA CA2955184A patent/CA2955184A1/en active Pending
- 2017-01-17 CN CN201780007730.6A patent/CN108473587A/zh active Pending
- 2017-01-17 JP JP2018538596A patent/JP6783312B2/ja not_active Expired - Fee Related
- 2017-01-17 EP EP17702687.9A patent/EP3408294A1/en not_active Withdrawn
- 2017-01-17 RU RU2018127164A patent/RU2748949C2/ru active
- 2017-01-17 US US16/069,712 patent/US20190031765A1/en not_active Abandoned
- 2017-01-17 BR BR112018014016A patent/BR112018014016A2/pt not_active IP Right Cessation
- 2017-01-17 MX MX2018008995A patent/MX2018008995A/es unknown
- 2017-01-17 KR KR1020187024267A patent/KR20180103150A/ko not_active Ceased
- 2017-01-17 HK HK19101614.3A patent/HK1259253A1/zh unknown
- 2017-01-17 WO PCT/IB2017/050244 patent/WO2017130076A1/en not_active Ceased
- 2017-01-17 KR KR1020217002980A patent/KR20210013777A/ko not_active Ceased
- 2017-01-17 AU AU2017211540A patent/AU2017211540B2/en not_active Ceased
-
2020
- 2020-07-27 AU AU2020210145A patent/AU2020210145A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506403A5 (https=) | ||
| RU2018127164A (ru) | Комбинация моноклональных антител агониста ох40 и агониста 4-1вв для лечения рака | |
| JP2017514795A5 (https=) | ||
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| JP2017506227A5 (https=) | ||
| JP2018522850A5 (https=) | ||
| JP2019517485A5 (https=) | ||
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| JP2015532292A5 (https=) | ||
| JP2017533912A5 (https=) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2020508317A5 (https=) | ||
| JP2015534577A5 (https=) | ||
| JP2019526595A5 (https=) | ||
| JP2010515709A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| JP2008528486A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| JP2022512851A5 (https=) | ||
| JP2012507499A5 (https=) | ||
| JP2021511372A5 (https=) | ||
| JP2020515577A5 (https=) |